


mProbe Assumes Operations of the OncoPlex Diagnostics Laboratory at Rockville, MD

mProbe announced they have licensed the OncoPlex Diagnostics technology, IP and will take over the operation of the OncoPlex Diagnostics lab site at Rockville.

MOUNTAIN VIEW, CA, USA, April 22, 2020 /EINPresswire.com/ -- mProbe Inc. is a leading biotechnology company offering a suite of healthcare solutions to empower precision medicine, precision health, and precision healthcare analytics. mProbe announced they have licensed the OncoPlex Diagnostics technology, IP and will take over the operation of the OncoPlex Diagnostics lab site at Rockville, MD. This enables mProbe to offer a series of precision oncology diagnostic tests through mProbe's OncoOmicsDx product suite.



Phenotypical Expression Key to Precision Medicine

mProbe specializes in the deep phenotyping of tumor tissue, providing oncologists with unparalleled diagnostic insights to the mechanism of action that drives an individual patient's tumor biology. Applying this core technology through mProbe's OncoOmicsDx testing enables treating oncologists to match patient tumor molecular profiles to FDA approved therapies as well as novel targeted therapies

in clinical trials. Together, these capabilities provide personalized therapeutic options optimally suited to deliver effective cancer care based on each patient's unique tumor biology. mProbe's proprietary quantitative proteomic clinical assays have been validated through numerous multicenter studies and peer review publications. OncoOmicsDx, a novel multiplexed method of providing tumor protein quantitation matched to therapeutic mechanism of action, is one of the most sensitive and specific detection tools available exclusively through mProbe's CAP-CLIA certified laboratory.

“

We are building a clinical population baseline of patient and tumor phenotyping through metabolomic and proteomic for precision health and precision medicine”

Dr. Karl Sylvester, Chairman of the Medical Advisory Board for mProbe

“Tumor biology is complex and at the cellular level oncoprotein expression is quite unique regardless of the

genotype”, said Dr. Robert Heaton, the mProbe Chief Pathologist. “Precision medicine requires precision diagnostics and precision diagnostics requires a cellular view.”

“We are building a clinical population baseline of patient and tumor phenotyping through metabolomic and proteomic for precision health and precision medicine.” explained Dr. Karl Sylvester, Chairman of the Medical Advisory Board for mProbe. “The addition and expansion of

the OncoOmicsDx product suite coupled with mProbe's deep expertise in mass spectrometry phenotyping will advance our mission to deliver precision diagnostics in cancer care.

About mProbe

mProbe Inc. is a leading biotechnology company founded out of Stanford University, promoting human health and wellness by transforming the field of Precision Medicine, Precision Health, and Precision Healthcare Analytics. mProbe has developed a proprietary technology integrating artificial intelligence and multi-omic diagnostics to transform the disease prediction, prevention, and cure paradigm. For more information, please visit <http://www.mprobe.com>.

mProbe Maryland Laboratory is the only CAP-accredited, CLIA-certified laboratory with the unique and proprietary capability to solubilize tumor cell proteins from FFPE tissue for quantitation of oncology biomarkers by mass spectrometry analysis. For more information about mProbe precision oncology tests, please visit <http://www.oncoomicsdx.com>.

LAURA KANOV

mProbe, Inc

+1 615-392-5201

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2020 IPD Group, Inc. All Right Reserved.